Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06151210
Other study ID # DA5219_GAS_III
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 31, 2024
Est. completion date December 2024

Study information

Verified date April 2024
Source Dong-A ST Co., Ltd.
Contact Hwoon-Yong Jung, Ph.D
Phone +82) 02-3010-3197
Email hwoonymd@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the efficacy and safety of DA-5219 in patients with acute or chronic gastritis


Recruitment information / eligibility

Status Recruiting
Enrollment 452
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 75 Years
Eligibility Main Inclusion Criteria: - Men or women aged = 19 years and = 75 years - Subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization - Subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization - Subjects who voluntarily signed a consent form Main Exclusion Criteria: - Ineligible for upper gastrointestinal endoscopy - Subjects with active or healing gastroduodenal ulcer, reflux esophagitis, Barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization - Subjects with hypersensitivity to investigational drugs and similar drugs - Pregnant or breastfeeding women

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
DA-5219
1 tablet/day
Stillen® Tab
3 tablets/day
DA-5219 Placebo
1 tablet/day
Stillen® Tab Placebo
3 tablets/day

Locations

Country Name City State
Korea, Republic of Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Dong-A ST Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement rate of gastric mucosal erosion Change from baseline at 2 weeks
Secondary Cure rate for gastric mucosal erosion Change from baseline at 2 weeks
Secondary Cure rate for gastric mucosal edema Change from baseline at 2 weeks
Secondary Improvement rate for gastric mucosal erythema Change from baseline at 2 weeks
Secondary Improvement rate for gastric mucosal bleeding Change from baseline at 2 weeks
Secondary Improvement rate for gastric subjective symptoms Change from baseline at 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT05163756 - To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient Phase 3
Completed NCT03443804 - To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients Phase 3
Active, not recruiting NCT04702542 - To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children. N/A
Completed NCT06269380 - Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy N/A